IRIS - Res&Arch Institutional Research Information System - Research & Archive

RIUZZI, Francesca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.566
EU - Europa 2.574
AS - Asia 2.503
SA - Sud America 530
AF - Africa 43
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 4
Totale 9.225
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.488
SG - Singapore 1.020
IT - Italia 477
UA - Ucraina 469
HK - Hong Kong 463
BR - Brasile 457
IE - Irlanda 440
CN - Cina 364
RU - Federazione Russa 252
VN - Vietnam 207
KR - Corea 192
DE - Germania 180
SE - Svezia 179
FI - Finlandia 134
GB - Regno Unito 108
RO - Romania 53
NL - Olanda 49
AT - Austria 43
CA - Canada 43
FR - Francia 42
TR - Turchia 42
IN - India 40
PL - Polonia 30
AR - Argentina 29
JP - Giappone 29
CH - Svizzera 22
ES - Italia 22
BD - Bangladesh 21
BE - Belgio 19
IQ - Iraq 18
MX - Messico 18
CZ - Repubblica Ceca 17
PH - Filippine 15
EC - Ecuador 13
ZA - Sudafrica 12
ID - Indonesia 11
UZ - Uzbekistan 11
LB - Libano 10
CO - Colombia 9
CL - Cile 8
EG - Egitto 8
IR - Iran 7
MA - Marocco 7
PK - Pakistan 7
MD - Moldavia 6
AE - Emirati Arabi Uniti 5
GR - Grecia 5
IL - Israele 5
JM - Giamaica 5
LT - Lituania 5
PE - Perù 5
TH - Thailandia 5
TN - Tunisia 5
TW - Taiwan 5
VE - Venezuela 5
MY - Malesia 4
PY - Paraguay 4
AZ - Azerbaigian 3
BG - Bulgaria 3
DO - Repubblica Dominicana 3
EU - Europa 3
HU - Ungheria 3
KH - Cambogia 3
NZ - Nuova Zelanda 3
PA - Panama 3
SA - Arabia Saudita 3
AU - Australia 2
BA - Bosnia-Erzegovina 2
CR - Costa Rica 2
DK - Danimarca 2
GT - Guatemala 2
HR - Croazia 2
JO - Giordania 2
KE - Kenya 2
KG - Kirghizistan 2
KW - Kuwait 2
KZ - Kazakistan 2
LV - Lettonia 2
NP - Nepal 2
RS - Serbia 2
AF - Afghanistan, Repubblica islamica di 1
AL - Albania 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
ET - Etiopia 1
IS - Islanda 1
ME - Montenegro 1
MW - Malawi 1
NG - Nigeria 1
NO - Norvegia 1
PS - Palestinian Territory 1
QA - Qatar 1
RE - Reunion 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SO - Somalia 1
SV - El Salvador 1
TG - Togo 1
TT - Trinidad e Tobago 1
TZ - Tanzania 1
Totale 9.224
Salva come PNG Salva come JPEG
Città #
Singapore 738
Chandler 543
Hong Kong 453
Dublin 436
Jacksonville 255
San Mateo 228
Ashburn 184
Boardman 177
Perugia 167
Santa Clara 152
Seoul 127
Medford 107
Wilmington 107
Princeton 106
Dong Ket 94
Ann Arbor 89
Beijing 82
Moscow 80
Altamura 75
The Dalles 61
Andover 59
Los Angeles 59
Munich 52
New York 51
Lawrence 49
Piscataway 48
Bucharest 47
Des Moines 45
Ho Chi Minh City 44
São Paulo 35
Falls Church 33
Dearborn 32
Vienna 30
Norwalk 28
Helsinki 27
Bologna 25
Saint Petersburg 25
Redmond 24
Shanghai 24
Tokyo 23
Hanoi 20
Rio de Janeiro 20
Montreal 19
Brussels 18
Seongnam-si 18
Warsaw 18
Woodbridge 18
Turku 17
Stockholm 16
Falkenstein 15
Amsterdam 14
Boston 14
Council Bluffs 14
Dallas 14
Houston 14
London 14
Phoenix 14
Brooklyn 13
Izmir 13
Chicago 12
Nuremberg 11
Olomouc 11
Redwood City 11
Denver 10
San Francisco 10
Brasília 9
Chennai 9
Groningen 9
Johannesburg 9
Milan 9
Parma 9
Philadelphia 9
Ankara 8
Atlanta 8
Columbus 8
Incheon 8
Istanbul 8
Orem 8
Rome 8
Baghdad 7
Cebu City 7
Frankfurt am Main 7
Glasgow 7
Guangzhou 7
Manchester 7
Mumbai 7
Seodaemun-gu 7
Toronto 7
Auburn Hills 6
Cairo 6
Collazzone 6
Dhaka 6
Guarulhos 6
Guayaquil 6
Hefei 6
Osasco 6
Tashkent 6
Vicenza 6
Belo Horizonte 5
Caxias do Sul 5
Totale 5.641
Salva come PNG Salva come JPEG
Nome #
An HMGB1/RAGE/p38 MAPK/Myogenin Axis Modulates Pax7 Expression in Myoblasts by Both Transcriptional and Post-Transcriptional Mechanisms 139
RAGE in the pathophysiology of skeletal muscle. 126
Activation of RAGE in myoblasts and rhabdomyosarcoma cells results in downregulation of Pax7 expression 122
Differential expression of S100B protein and RAGE in young and aged human satellite cells. 122
Targeting RAGE prevents muscle wasting and prolongs survival in cancer cachexia 122
Sertoli cells protect C2C12 myotubes against atrophy and induce utrophin expression in canine and human dystrophic myotubes. 121
Identification of natural products able to counteract the formation of advanced glycation end-products (AGEs) sustaining muscle atrophy 121
Oxidative stress-induced S100B accumulation converts myoblasts into brown adipocytes via an NF-κB/YY1/miR-133 axis and NF-κB/YY1/BMP-7 axis 120
Amphoterin-induced myogenic differentiation of RAGE-transfected rhabdomyosarcoma TE671 cells 119
S100B protein regulates myoblast and macrophage functions in skeletal muscle regeneration 118
A braking circuit between pathogen- and danger-sensing signaling pathways restrains lung inflammation: role of S100B protein, RAGE and Toll-like receptors. 117
RAGE signalling in myoblasts and embryonal rhabdomyosarcoma cells represses Pax7 expression via p38 MAPK-dependent induction of myogenin. 115
Aged vs young human satellite cells: altered expression of S100B and RAGE, and defective ability in conditioning the medium contribute to impaired myogenic potential. 115
Cellular and molecular mechanisms of sarcopenia: the S100B perspective 114
RAGE expression in rhabdomyosarcoma cells results in reduced proliferation, migration, and invasiveness in vitro and tumor growth in vivo 112
Toward the identification of receptor for advanced glycation end-products (RAGE) as a muscle biomarker of cancer cachexia. 112
Equisetum arvense standardized extract hinders age-related sarcopenia 110
Amphoterin stimulates myogenesis and counteracts the anti-myogenic factors, bFGF and S100B, via RAGE binding 110
RAGE and its ligands, S100B and HMGB1, are molecular determinants of cancer-induced muscle wasting. 109
Natural products to counteract muscle atrophy 109
Targeting RAGE as a potential therapeutic approach to Duchenne muscular dystrophy 106
Pharmacological targeting of the receptor for advanced glycation end-products (RAGE) to counteract cancer cachexia 103
Sertoli cell-secreted factors have promyogenic and antifibrotic properties on human DMD myoblasts with different mutations. 103
Implication of RAGE and Amphoterin in Myogenesis 102
Absence of RAGE in an animal experimental model of Duchenne muscular dystrophy results in reduced muscle necrosis and inflammation 102
Glyoxalase 1 sustains the metastatic phenotype of prostate cancer cells via EMT control 101
Screening of 100 plant extracts for the development of a herbal product effective against muscle atrophy 101
Beneficial effects of horsetail (Equisetum arvense) in experimental models of sarcopenia and osteoporosis 100
Microencapsulated Sertoli cells sustain myoblast proliferation without affecting the myogenic potential. In vitro data 97
Different intrinsic properties of young and aged human satellite cells. 95
Hypoxia Promotes Danger-mediated Inflammation via Receptor for Advanced Glycation End Products in Cystic Fibrosis 95
Appropriate levels of extracellular S100B protein in injured muscle are required for correct muscle regeneration. 91
RAGE engagement in myoblasts modulates proliferation, apoptosis, adhesiveness, migration and invasiveness 90
Identification of Withania somnifera-Silybum marianum-Trigonella foenum-graecum Formulation as a Nutritional Supplement to Contrast Muscle Atrophy and Sarcopenia 90
Opposing regulatory roles of S100B and amphoterin in myogenic differentiation: RAGE-dependence of amphoterin stimulatory effects vs. RAGE-independence of S100B inhibitory effects 88
S100B protein, a damage-associated molecular pattern protein in the brain and heart, and beyond 88
Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite 88
KYMASIN UP Natural Product Inhibits Osteoclastogenesis and Improves Osteoblast Activity by Modulating Src and p38 MAPK 87
Levels of S100B protein drive the reparative process in acute muscle injury and muscular dystrophy 87
Do porcine Sertoli cells represent an opportunity for Duchenne muscular dystrophy? 87
Effects of deletion of RAGE in muscle regeneration: preliminary observations. 86
Genetically-determined hyperfunction of the S100B/RAGE axis is a risk factor for aspergillosis in stem cell transplant recipients 86
The receptor RAGE: a potential molecular target in cancer cachexia 86
Employment of Microencapsulated Sertoli Cells as a New Tool to Treat Duchenne Muscular Dystrophy 86
RAGE signaling in myoblasts and rhabdomyosarcoma cells causes downregulation of Pax7 expression via p38 MAPK activation and upregulation of myogenin expression 85
Young and Aged Human Muscle Satellite Cells Show Differential Expression of S100B Protein and RAGE. 84
S100B protein in tissue development, repair and regeneration 84
RAGE-independence of S100B inhibition of myogenic differentiation and myotube formation 83
Complex regulatory effects of extracellular S100B on myoblast differentiation: S100B activates quiescent myoblats and satellite cells 82
Functional inactivation of RAGE in myoblasts results in tumor formation 82
S100B protein differentially regulates myoblast differentiation via direct binding to RAGE and bFGF-mediated activation of FGFR1 in low-density and high-density cultures, respectively 82
S100B causes apoptosis in a myoblast cell line in a RAGE-independent manner 82
The danger signal S100B integrates pathogen- and danger-sensing pathways to restrain inflammation 82
Causes of elevated serum levels of S100B protein in athletes 82
Elucidating the mechanism of S100B-dependent regulation of myoblast differentiation. 81
Defective RAGE activity in embryonal rhabdomyosarcoma cells results in high PAX7 levels that sustain migration and invasiveness 81
Hyperactivated rage in comorbidities as a risk factor for severe covid-19—the role of rage-ras crosstalk 80
Use of Sertoli cells to treat DMD patients is supported by their immunomodulatory rather than immunosuppressive effect 79
Molecular mechanism of S100B-dependent inhibition of myoblast differentiation 78
Involvement of a RAGE/p38MAPK/myogenin axis in cancer cachexia. 78
Differential involvement of RAGE and FGFR1 in S100B effects on myoblast differentiation 76
Human muscle satellite cells show age-related differential expression of S100B protein and RAGE. 76
Functions of S100 proteins 76
Caveolins and cavins in muscle-derived tumours. 76
S100 proteins in obesity: liaisons dangereuses 76
Receptor for advanced glycation end-products (RAGE) as a biomarker of muscle wasting in cancer conditions 75
Ablation of RAGE (receptor for advanced glycation end-products) translates into reduced tumorigenic and cachectic potential in LLC-tumor bearing mice 74
S100B-dependent inhibition of myoblast differentiation: molecular mechanism 74
Potential role of S100B protein in myogenesis and skeletal muscle regeneration 74
S100B engages RAGE or bFGF/FGFR1 in myoblasts depending on its own concentration and myoblast density. Implications for muscle regeneration 74
Reductive stress in striated muscle cells 74
HMGB1/RAGE modulates Pax7 expression in myoblasts via p38 MAPK-dependent upregulation of myogenin. 73
Equisetum arvense standardized dried extract hinders age-related osteosarcopenia. 70
S100B activates quiescent myoblasts and satellite cells 70
Delayed Muscle Regeneration in RAGE-/- Skeletal Muscles. 70
S100B causes apoptosis in myoblasts and inhibits myogenic differentiation and myotube formation in a RAGE-independent manner 69
Mechanism of S100B-dependent inhibition of myoblast differentiation 69
S100B activates muscle satellite cells via RAGE engagement 69
S100B protein accelerates the activation of quiescent myoblasts and muscle satellite cells. 69
Novel data support the use of microencapsulated Sertoli cells as a potential treatment of DMD patients. 69
Effects of RAGE expression in rhabdomyosarcoma cells 67
RAGE modulates myoblast proliferation, apoptosis, migration and invasiveness 67
RAGE expression in rhabdomyosarcoma cells results in myogenic differentiation and reduced proliferation, migration, invasiveness, and tumor growth 67
Differential engagement of RAGE and FGFR1 in muscle satellite cells by S100B protein: involvement of RAGE in satellite cell activation and of FGFR1 on satellite cell expansion. 67
The amphoterin (HMGB1)/receptor for advanced glycation end products (RAGE) pair modulates myoblast proliferation, apoptosis, adhesiveness, migration, and invasiveness. Functional inactivation of RAGE in L6 myoblasts results in tumor formation in vivo 66
Phosphocaveolin-1 Enforces Tumor Growth and Chemoresistance in Rhabdomyosarcoma 66
S100B protein in skeletal muscle regeneration: regulation of myoblast and macrophage functions 66
RAGE transduces antiproliferative, pro-apoptotic and anti-tumor signals in myoblasts 65
Spatiotemporal regulation of Toll-like receptors and RAGE signaling pathways by S100B protein restrains inflammation 64
Role of CD45 signaling pathway in Galactoxylomannan-induced T cell damage. 63
Enforced expression of RAGE in rhabdomyosarcoma cells result in reduced proliferation, migration, and invasiveness in vitro, activation of a myogenic program, and reduced tumor growth in vivo. 63
RAGE in tissue homeostasis, repair and regeneration. 63
S100B inhibits myogenic differentiation and myotube formation in a RAGE-independent manner 62
The many faces of S100B protein: when an extracellular factor inactivates its own receptor and activates another one. 62
Sertoli cells induce utrophin expression in human DMD myotubes with different mutations and exert promyogenic and antifibrotic effects 61
S100B's double life: Intracellular regulator and extracellular signal. 61
RAGE expression in rhabdomyosarcoma cells modulates metastasis formation in vivo. 61
The novel DMD experimental model, mdx/Ager–/– mouse reveals a role of RAGE in inflammatory processes in dystrophic muscles. 61
Re-expression of RAGE in damaged skeletal muscles: RAGE-/- mice show delayed muscle regeneration 60
S100B inhibits myoblast differentiation via activation of a Ras-MEK-ERK1/2 signaling pathway 58
Totale 8.626
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.648
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.648
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021428 0 0 0 0 0 46 81 6 91 18 75 111
2021/2022938 7 168 26 43 33 20 16 264 19 44 110 188
2022/20231.620 134 273 28 131 133 184 2 76 571 4 60 24
2023/2024737 43 70 29 31 15 18 211 23 80 16 87 114
2024/20252.294 55 203 165 106 297 109 203 208 358 122 340 128
2025/20262.018 267 220 181 537 548 265 0 0 0 0 0 0
Totale 9.480